biostudies-literatureUnknown73Abdalla-Aslan R<h4>Background</h4>Mucositis is a common and highly impactful side effect of conventional and emerging cancer therapy and thus the subject of intense investigation. Although common practice, mucositis assessment is heterogeneously adopted and poorly guided, impacting evidence synthesis and translation. The Multinational Association of Supportive Care in Cancer (MASCC) Mucositis Study Group (MSG) therefore aimed to establish expert recommendations for how existing mucositis assessment tools should be used, in clinical care and trials contexts, to improve the consistency of mucositis assessment.<h4>Methods</h4>This study was conducted over two stages (January 2022-July 2023). The first phase involved a survey to MASCC-MSG members (January 2022-May 2022), capturing current practices, challengEClinicalMedicine102675https://www.ebi.ac.uk/biostudies/studies/S-EPMC11200283biostudies-literatureGuidance on mucositis assessment from the MASCC Mucositis Study Group and ISOO: an international Delphi study.PMC11200283Melo ACMBrito-Dellan NTeixeira AMartins GMartins FSerrano VMarinho JMatsuda YCorbitt NKnuchel MMougeot JLTomizuka KLaheij Ade Mooij CFliedner MPalma PNeri JStringer AIacovelli NADantas JMoreira AAlves FSkallsjo KReeder LSouza MSantos PSRaber-Durlacher JPieralisi NChaturvedi PWhite KCao KGranzotto FKeefe DPotter GMcKeage LSantos ISantos MJensen SBMiller RSales RSamuel SRMauceri RAl-Jamaei AGruza AFulop CBlazy AKovalenko IJaya VangaraMASCC Mucositis Study Groupde Moraes TSelvaraj VKOngole RHong CUsubuchi MZadik YBeaumont SPortela LTaleghani MBrzak BLTorino GJungbluth HPJulie PfefferAmaral Mendes RLemenchick OAl-Qadami GColler JSaunders DGilbert SPoh CLais Dos Santos HBaad-Hansen LWilberg PDave KMigliorati CNakamura MBonomo PBarbosa LSBGarcia RLoprinzi CHoeberechts GGarcia NKatsura KEhrenpreis ECampos LHarilall AJunior RArvanitou EBowen JMelvin AFritz PAielli FBruning EBrown-Dahl APerez DBlanchard APolonskaia AGuerra LMori TSpeksnijder CMGenot MTPassos JSoga YBossi PBorin RCHansen HKabasawa YDennis KGueiros LKataoka TAnderson CKelock TVigarios EKandwal ASonis SPatrick CNeumann ECooper KGordon SSoares ALNicolatou-Galitis OChugh DCamilotti RBlijlevens NFox JBuick DRybczyk CEpstein JKurtzweil ACarlesimo MSchmeel LGaliti DPeterson DTravassos DDel Conte CMelo MDGKarra NTrager STsoukalas NTetsuhito KonishiNunes DPaz ASMendes ORupel KHewson ITest BHauer-Jensen MAl-Azri ARCole MYeoh KManne DTaybos GKauark-Fontes EBarczyszyn KMadureira EBalajiSubramanian SYurikusa TJasper JRistivojevic JJVilla AYergolkar AVHovan AThota RKaffenberger BAlbini GFonseca DFonseca FFonseca IFlaitz CLang LFreites-Martinez AUezu KMuzyka BDjordjevic FNasr NAndrade PAndrade MMcCullough RHerlofson BBSkrinjar IFregnani ERHowarth GGiannini ALeong IKurup SFerrari RFramroze BHuang TWAbdalla-Aslan RTiwari PMcCarvell VSpekssnijder CChoi YCRibeiro DPolvora TSFontes EKWeng HBruno JWeld HMiranda E Silva WTunes RBrennan MIllarramendi JNair RVenkatesh NGrando LMajorana ASalaberry ASpijkervet FSantos GDSaganski KGururaj RStokman MGomes-Silva WChoy MLogan RMainville GGore AElsayed MDe Bortolli JMendes RASeo SGross CLynge Pedersen AMHorvath AArends JFreytes CRoser SChambers MKase MAngeloz SWeikel DGibson RReis PGkardiakos GGadd NBernard SPon DFinkelstein JTaylor SGandini CSkulski SCheung YTDulmage BWardill HRRossi CBryan GEl Maghrabi AFreidank AJain KSilva PKuriakose JGomez Amarilla MCSarmento VRogulj AAAbbott DSilva GNagano CDougan MSilva CRego RFortuna MCKelly TGobbo MMunhoz ELima KSShazib MAVolkova EGirons PSda Silveira GHasan ILalla RMenezes LRamires MMcInnes HPereira MSalvestrini VAmaram-Davila JTissing WBardellini ENeves MRuddy KBradley GMarkova ANakagaki MFaleiro SCaldas RKomo IPeters EBraun LCantoreggi SHasseus BCarlisle SBiggs KVerma GParker IHendler Kde Oliveira SThirlwell MFernandes TVirgen CMontezuma MPoropat AMarkstrom DReese SMougeot FKwong BKauzman ARamseier ACurvo ARMaitra SOttaviani GMukhopadhyay SBrito JBuga SMeurer JMcCurdy-Franks EFranco MCBernaola-Paredes WSperandio FPettersson BWardill HScott JDiniz-Freitas MRobijns JHeng VSamim FAdebayo-Olojo ELeko JBektas-Kayhan KRadford GPrado RASiderov JMuniz LMonsen RFernandez-Ortega PGussgard AMCarvalho FRandles-Guzzardi MAriyawardana AGomez JAbasaeed RSundaresan DLacerda VCardoso EPapadopoulou ELim MElad SBenites BJanine Tam SYNeuenschwander CMantelato CVan Sebille BPeiris DLenjisa JAvon SLTanda Nvan Draanen LSantos-Silva AWeaver DFregnani EMinamisako MVan Sebille YHardman AMSankar S PI'zzah Wan Mohamad Zain WNShchitka VAraujo MFerreira TARibeiro ACNazar MAgatti LThermann AFeitoza REngelbrecht HFlato ADSLCaro GLee NChiantia FSaini RSinghai PRiesenbeck DSemendric ISankaran SPSecombe KTanaka KMitsunaga SHodgins KKolbinson DFernandez LZanicotti RSimonato LRastogi MSomogyi-Ganss EGardner PBoers-Doets CKaprilian MBouchacourt MCiarrocca KShatokhina EYokota TWu JPigatti FCarroll JRiad MHata HFall-Dickson JGarzona-Navas LBrown Cda Silva SMenge RTorregrossa VElting LKalif IFilho AMSaeki TTilly VMassoud CYang DZelaya FCMelo ABatista NPalmier NUllgren HBeck-Mannagetta JGunathilake SVitor MSubramaniam CSampaio NLPark WHarding JAntunes HSTonkaboni AYarom NPowers JMizutani MGoldemberg DCvan Leeuwen SMorgan AKoizumi AHiguchi TMazar AIossi LSeshadri MBallantyne BMackey RVon Bultzingslowen IBensadoun RJBrown TDe Vandeul TMMonteiro JBrown SWain TfalseGuidance on mucositis assessment from the MASCC Mucositis Study Group and ISOO: an international Delphi study.<h4>Background</h4>Mucositis is a common and highly impactful side effect of conventional and emerging cancer therapy and thus the subject of intense investigation. Although common practice, mucositis assessment is heterogeneously adopted and poorly guided, impacting evidence synthesis and translation. The Multinational Association of Supportive Care in Cancer (MASCC) Mucositis Study Group (MSG) therefore aimed to establish expert recommendations for how existing mucositis assessment tools should be used, in clinical care and trials contexts, to improve the consistency of mucositis assessment.<h4>Methods</h4>This study was conducted over two stages (January 2022-July 2023). The first phase involved a survey to MASCC-MSG members (January 2022-May 2022), capturing current practices, challeng2024-01-01T00:00:00Z2024 Jul2025-06-01T01:38:59.415Z2025-06-01T01:38:59.415ZS-EPMC112002833893309810.1016/j.eclinm.2024.102675